

Annex – list of selected projects

Title	Coordinator	Amount	Project Scope
▪ EbolaVac	GlaxoSmithKline Biologicals, BE	€15,153,216	Conduct clinical trials in Europe and Africa on the most advanced vaccine candidate ChAd3-EBOV. These trials will provide extended evidence on the safety and ability to elicit a protective immune response, as well as on the most appropriate vaccination schedule. These trials are the necessary step toward studies on the protective effect of the vaccine that will follow.
▪ REACTION	Institut National de la Sante et de la Recherche Medicale (INSERM), FR	€2,575,810	Study the safety and efficacy of Favipiravir, an antiviral already licensed for influenza, first in an animal model of the disease and then on patients with Ebola virus disease. First results expected after 6 months.
▪ Ebola_Tx	Prins Leopold Instituut voor Tropische Geneeskunde, BE	€2,892,171	Study the safety, efficacy, and practical aspects of using whole blood or plasma from survivors, as a treatment for patients with Ebola virus disease.
▪ EVIDENT	Bernhard-Nocht-Institut fuer Tropenmedizin, DE	€1,759,326	Research on interactions between the Ebola virus and the host. This will provide urgently needed answers regarding the pathophysiology and transmissibility of the disease, and will help better guide the planned clinical trials on vaccines and potential treatments, as well as the management of patients with Ebola virus disease.
▪ IF-EBola	Institut de Recherche pour le Developpement, FR	€1,992,770	Study the safety and efficacy of using antibodies produced in horses against Ebola, as a passive immunity treatment for patients with Ebola virus disease.
		€ 24,373,293	